Open AccessAssessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma
Author(s) -
Hao Duan,
Ji-Long Hu,
Zhenghe Chen,
Jue-hui Li,
Zhenqiang He,
Zhenning Wang,
Guanhua Zhang,
Xiaoyu Guo,
Lingming Liang,
Yonggao Mou
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000843
Subject(s) - cerebrospinal fluid , exome sequencing , temozolomide , isocitrate dehydrogenase , dna sequencing , idh1 , mutation , medicine , exome , cancer , pathology , brain tumor , glioblastoma , cancer research , oncology , biology , dna , gene , genetics , biochemistry , enzyme
Cerebrospinal fluid (CSF) has been demonstrated as a better source of circulating tumor DNA (ctDNA) than plasma for brain tumors. However, it is unclear whether whole exome sequencing (WES) is qualified for detection of ctDNA in CSF. The aim of this study was to determine if assessment of ctDNA in CSF by WES is a feasible approach to detect genomic alterations of glioblastoma.